Intellectual Property

IP Portfolio

Patent-protected methods for treating alcohol use disorder using retatrutide

Methods of Treating Alcohol Use Disorder and Related Conditions Using Retatrutide

U.S. Nonprovisional Utility Patent Application No. 19/705,839
Patent Pending
June 12, 2026
19/705,839
App. 64/087,892
36 Claims
10 Independent
2 Sheets

Abstract

Disclosed are methods of treating alcohol use disorder (AUD) and related conditions in human subjects using retatrutide, a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). The methods include monotherapy, combination therapy with naltrexone (a mu-opioid receptor antagonist), and synergistic dual-pathway treatment approaches. Claims cover methods of reducing alcohol craving, reducing relapse, modulating central reward pathway signaling, and dose-sparing combination regimens.

Independent Claim Families (10 Total)

Claims 1–10Retatrutide monotherapy for AUD — dosing, comorbidities, outcomes
Claims 11–13Reducing alcohol craving with retatrutide
Claims 14–15Reducing relapse to heavy alcohol use
Claim 16Modulating central reward pathway signaling via GLP-1R
Claims 17–24Combination therapy: retatrutide + naltrexone
Claim 25Simultaneous opioid + GLP-1 pathway modulation
Claims 26–29Synergistic reduction of alcohol consumption
Claims 30–32Synergistic reduction of alcohol craving
Claims 33–35Synergistic prevention of relapse
Claim 36Dose-sparing combination at sub-therapeutic doses

Differentiation from Prior Art

No prior art discloses retatrutide for AUD treatment, or GCGR agonism for any addictive disorder. Competitive differentiation:

CompoundGLP-1RGIPRGCGRAUD Indication
Semaglutide✓✗✗Not patented
Tirzepatide✓✓✗Not patented
Retatrutide (our patent)✓✓✓✓ Patented

Interested in Licensing?

We welcome inquiries from pharmaceutical companies seeking to license these methods for clinical development and commercialization.

Contact Us